Rockwell Medical sees Q2 revenue rise 11% to $17.8 million

• Rockwell Medical (NASDAQ:RMTI) reported Q2 2026 net sales of $17.8 million, up 11% year over year, with gross profit increasing 30%.
• The company reduced its quarterly net loss to $1.2 million and ended the period with $24.8 million in cash, cash equivalents, and investments.
• Rockwell Medical said it remains focused on achieving its 2026 guidance through revenue growth, margin improvements, and positive cash flow generation.

Rockwell Medical (NASDAQ:RMTI) reported second-quarter 2026 net sales of $17.8 million, up 11% year over year, as the healthcare company increased sales to new and existing dialysis customers.

The company’s quarterly revenue rose from $16.1 million in Q2 2025, while gross profit increased 30% to $3.2 million and gross margin expanded to 18% from 16%.

Rockwell Medical generated $2.1 million in operating cash flow during the quarter, reported a net loss of $1.2 million compared with a $1.5 million loss a year earlier, and recorded adjusted EBITDA of negative $0.2 million.

For the first six months of 2026, Rockwell Medical reported net sales of $35.1 million, gross profit of $6.1 million, a net loss of $2.8 million, and adjusted EBITDA of negative $0.4 million.

Rockwell Medical develops, manufactures, commercializes, and distributes hemodialysis products used by dialysis providers worldwide, with its portfolio focused on kidney care treatments.

The company ended June 30, 2026, with $24.8 million in cash, cash equivalents, and investments available for sale, compared with $23.9 million at the end of the first quarter, and said it remains focused on meeting its full-year guidance.